We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01058629
Recruitment Status : Unknown
Verified August 2010 by SynergEyes, Inc..
Recruitment status was:  Active, not recruiting
First Posted : January 28, 2010
Last Update Posted : August 25, 2010
Information provided by:
SynergEyes, Inc.

Brief Summary:
This is a multicenter study to evaluate the clinical performance of the SynergEyes A2 lens in patients with refractive errors with or without astigmatism.

Condition or disease Intervention/treatment
Refractive Errors Astigmatism Device: SynergEyes A2 Hybrid Contact Lens

Detailed Description:
Hybrid contact lenses have been previously shown to be a safe and effective method to correct refractive errors with and without astigmatism. The hybrid contact lens design may provide greater visual acuity and comfort than other soft or rigid gas permeable (RGP) lenses currently available. The purpose of this study is to confirm the design of the SynergEyes A2 lens by evaluating clinical performance and, if necessary, modify certain lens parameters in order to optimize lens performance. Objective and subjective parameters will be used to evaluate the lens.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 180 Day, Multicenter Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses for Daily Wear Use in the Correction of Refractive Error With or Without Astigmatism in Non-diseased Eyes
Study Start Date : August 2009
Estimated Primary Completion Date : September 2010
Estimated Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: SynergEyes A2 Hybrid Contact Lens Device: SynergEyes A2 Hybrid Contact Lens
SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.

Primary Outcome Measures :
  1. Confirm current SynergEyes A2 lens design by evaluating clinical performance using objective and subjective parameters [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Determine the best method for fitting the SynergEyes A2 hybrid contact lens [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Be able to understand and be willing to sign a written informed consent form
  • Age ≥18 years
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specific appointments
  • Have naturally occurring myopia up to -6.00 D or hyperopia up to +2.00 D (spectacle plane) with or without corneal astigmatism up to 6.00 D
  • Be in good general health, based on his/her knowledge, including normal healthy eyes
  • Possess wearable and visually functional eyeglasses
  • Have manifest refraction visual acuity equal to or better than 20/25 in each eye

Exclusion Criteria:

  • Subject requires multifocal vision correction or is wearing lenses in a monovision modality
  • Subject has lenticular astigmatism uncorrectable by normal RGP tear layer optics
  • Subject exhibits poor personal hygiene
  • Subject is currently or within 30 days prior to enrollment in this study has been an active participant in another clinical study (except SynergEyes Protocol # SI 08-05)
  • Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 9 months, or is lactating
  • Subject has a known sensitivity to ingredients used in contact lens care products
  • Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment
  • Subject is aphakic or pseudophakic
  • Subject has ocular or systemic disease such as, but not limited to, anterior uveitis or iritis (past or present), glaucoma, Sjogren's Syndrome, lupus erythematosus, scleroderma, keratoconus, post surgical corneal irregularity or type II diabetes
  • Subject is using ocular medications for any reason or systemic medications which might interfere with contact lens wear
  • A known history of corneal hypoesthesia (reduced corneal sensitivity)
  • Slit lamp findings that would contraindicate contact lens wear, including, but not limited to:

    • Evidence of corneal ulcer, corneal infiltrates or fungal infections
    • Corneal scars within the visual axis
    • Pterygium
    • Dry eye symptoms with decrease tear levels and punctuate staining ≥ Grade 2
    • Neovascularization or ghost vessels ≥1.5mm in from the limbus
    • Seborrhoeic eczema or seborrhoeic conjunctivitis
    • History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 or greater
  • Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids or associated structures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01058629

United States, California
Family Eye Care Center
Campbell, California, United States, 95008
SynergEyes, Inc.
Carlsbad, California, United States, 92008
Encino Optometric Center Corp.
Encino, California, United States, 91436
Carmel Mountain Vision Care
San Diego, California, United States, 92129
United States, Michigan
VisionCare Associates, PC
East Lansing, Michigan, United States, 48823
United States, Missouri
The Koetting Associates
St. Louis, Missouri, United States, 63144
United States, New York
Penfield, New York, United States, 14526
United States, Tennessee
Primary Eyecare Group
Brentwood, Tennessee, United States, 37027
United States, Washington
Specialty Eyecare Group Totem Lake Vision Center
Kirkland, Washington, United States, 98034
United States, Wyoming
Snowy Range Vision Center
Laramie, Wyoming, United States, 82070
Sponsors and Collaborators
SynergEyes, Inc.
Principal Investigator: Paul Kusy, OD, MS, FAAO SynergEyes, Inc.

Responsible Party: Jennifer Callahan, MAS/Manager of Clinical and Regulatory Affairs, SynergEyes, Inc.
ClinicalTrials.gov Identifier: NCT01058629     History of Changes
Other Study ID Numbers: SI 09-01
First Posted: January 28, 2010    Key Record Dates
Last Update Posted: August 25, 2010
Last Verified: August 2010

Keywords provided by SynergEyes, Inc.:
contact lens
near sighted
far sighted

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases